Compare Ally Financial Inc (ALLY) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Citius Pharmaceuticals Inc — how do they compare? Ally Financial Inc trades at $44.15 (market cap $13.32B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Ally Financial Inc is far larger — about 711.2× Citius Pharmaceuticals Inc's market cap, and Ally Financial Inc pays a 2.74% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALLY | CTXR | |
|---|---|---|
Market Cap | $13.32B | $18.73M |
Sector | Financials | Health |
52-Week High | $47.25 | $1.82 |
52-Week Low | $35.96 | $0.48 |
Dividend Yield | 2.74% | — |
Enterprise Value | — | $14.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.72, down 0.77% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 10.29 and P/B of 0.98, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations, causing a 2.4% decline, though revenue grew 10% year-over-year. The company maintains strong institutional support with 68% analyst buy ratings.
Outlook remains cautiously optimistic given the discounted valuation and solid fundamentals, though near-term pressure exists from recent earnings miss and insider selling. Key risks include credit quality concerns, interest rate sensitivity, and competitive pressures in auto lending. The 24% upside to consensus target suggests potential reward for patient investors despite technical weakness.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
